The U.S. Food and
Drug Administration originally approved the drug in 1999, but subsequent case reports of abnormal behavior in adolescents who used the medication led the agency in 2006 to require that all packaging of the drug include a warning label about potential neuropsychiatric side effects, such as hallucinations, delirium, self - harm and even suic
Drug Administration originally approved the
drug in 1999, but subsequent case reports of abnormal behavior in adolescents who used the medication led the agency in 2006 to require that all packaging of the drug include a warning label about potential neuropsychiatric side effects, such as hallucinations, delirium, self - harm and even suic
drug in 1999, but subsequent case reports
of abnormal behavior in adolescents who used the medication led the agency in 2006 to require that all packaging
of the
drug include a warning label about potential neuropsychiatric side effects, such as hallucinations, delirium, self - harm and even suic
drug include a warning label about potential
neuropsychiatric side effects, such as hallucinations, delirium, self - harm and even suicide.